Delphi Diagnostics Showcases Innovation at Leading Cancer Symposium
Delphi Diagnostics is set to make a significant impact with its presentation of four scientific abstracts at the highly anticipated San Antonio Breast Cancer Symposium. This event, recognized as the largest breast cancer research meeting worldwide, will be held in December and is expected to draw participants from over 100 countries.
About Delphi's Endocrine Activity Index
The spotlight will be on Delphi's innovative Endocrine Activity Index (EAI), which provides crucial insights into the sensitivity of breast cancer treatments. Known in scientific circles as the Sensitivity to Endocrine Therapy (SET) Test, the EAI aims to revolutionize treatment strategies for hormone receptor-positive HER2-negative breast cancer patients.
New Data to be Presented
The company will present a range of compelling findings during the symposium. Among the studies being emphasized is the ongoing analysis of data from the NRG/NSABP B-42 trial, which investigates the efficacy of extended endocrine therapy. This research aims to identify predictors of patient benefits from additional treatments, marking a critical advancement in breast cancer care.
Highlighted Abstracts
The accepted abstracts cover a diverse array of analyses, including:
- Evaluation of the EAI assay's capability to identify patient benefits from extended endocrine therapy.
- Exploratory findings on palbociclib benefits as determined by the SET index in earlier chemotherapy trials.
- Prognostic investigations pertaining to endocrine therapy sensitivity among diverse populations.
Chief Medical Officer, Federico A. Monzon, MD, stated, "The data from these studies enriches the clinical evidence for the EAI test. The oral presentation of results from the NRG/NSABP B-42 trial underscores the importance of understanding the endocrine activity pathway when navigating treatment options for breast cancer patients."
Commitment to Patient Care
Delphi Diagnostics remains dedicated to improving clinical outcomes for breast cancer patients. The company continuously seeks avenues to enhance patient care through scientifically validated testing.
About the Endocrine Activity Index
The EAI test serves as an actionable tool for identifying optimal chemotherapy plans for patients with stage II-III HR+ HER2- breast cancer. This test evaluates the endocrine activity of tumors and adjusts its findings based on significant clinical factors to provide a refined prognosis.
Impact on Clinical Outcomes
Research indicates that the EAI is a reliable predictor of long-term survival, acting independently of other common prognostic assessments. As such, it stands as an essential resource for tailoring treatment options.
About Delphi Diagnostics
Delphi Diagnostics Inc., based in Texas, focuses on advancing clinically validated tests aimed at enhancing breast cancer treatment strategies. With an exclusive licensing agreement from The University of Texas MD Anderson Cancer Center, the company works diligently to commercialize the Endocrine Activity Index, a technique developed by Dr. W. Fraser Symmans. Delphi's vision is clear: to provide personalized solutions for breast cancer patients.
Frequently Asked Questions
What is the Endocrine Activity Index?
The Endocrine Activity Index is a diagnostic test that assesses the sensitivity of breast tumors to endocrine therapy, helping to guide treatment decisions.
When is the San Antonio Breast Cancer Symposium taking place?
The symposium will occur in December, attracting thousands of participants worldwide to discuss advances in breast cancer research.
Who is presenting at the symposium?
Delphi Diagnostics will present findings from leading researchers in the field, focusing on the implications of their recent studies.
How does the EAI improve treatment decisions?
The EAI provides clinicians with valuable insights into treatment options, thereby improving the effectiveness of hormone therapy for patients.
What is Delphi's main goal?
Delphi's primary goal is to enhance patient care in breast cancer treatment through scientifically validated diagnostic testing and personalized medicine.
